FOLD - Amicus Therapeutics beats Q3 top and bottom line estimates; raises FY23 Galafold revenue outlook
2023-11-08 07:06:18 ET
More on Amicus Therapeutics
- Amicus Therapeutics: The Right Play Now
- Amicus Therapeutics: Limited Label For Pombiliti And Opfolda And Why It May Not Matter
- Amicus: Holding Until AT-GAA U.S. Approval
- Amicus in pact with Blackstone for $430M financing
For further details see:
Amicus Therapeutics beats Q3 top and bottom line estimates; raises FY23 Galafold revenue outlook